The 3 most recent market catalysts affecting $RCKT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15
Wedbush analyst Yun Zhong maintained an 'Outperform' rating on Rocket Pharmaceuticals (RCKT) but lowered the price target from $16 to $15. This action signals that while the analys…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 95
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate
Rocket Pharmaceuticals announced its Q2 adjusted EPS, reporting a loss of $(0.37) per share, which dramatically missed the analyst consensus estimate of a $0.24 gain. This 254.17% …
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease
Rocket Pharma reported that the initial three patients treated with RP-A501 for Danon disease under a modified protocol showed positive safety, with no thrombotic microangiopathy (…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.